Neglected mycobiome in HIV infection: Alterations, common fungal diseases and antifungal immunity

Shuang Li1,2, Xiaodong Yang1,2, Christiane Moog3,4, Hao Wu1,2, Bin Su1,2* and Tong Zhang1,2*

1Beijing Key Laboratory for HIV/AIDS Research, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, China, 2Sino-French Joint Laboratory for Research on Humoral Immune Response to HIV Infection, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, China, 3Laboratoire d’Immunorhumatologie Moléculaire, Institut national de la santé et de la recherche médicale (INSERM) UMR_S 1109, Institut thématique interdisciplinaire (ITI) de Médecine de Précision de Strasbourg, Transplantex NG, Faculté de Médecine, Fédération Hospitalo-Universitaire OMICARE, Fédération de Médecine Translatoire de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France, 4Vaccine Research Institute (VRI), Créteil, France

Human immunodeficiency virus (HIV) infection might have effects on both the human bacteriome and mycobiome. Although many studies have focused on alteration of the bacteriome in HIV infection, only a handful of studies have also characterized the composition of the mycobiome in HIV-infected individuals. Studies have shown that compromised immunity in HIV infection might contribute to the development of opportunistic fungal infections. Despite effective antiretroviral therapy (ART), opportunistic fungal infections continue to be a major cause of HIV-related mortality. Human immune responses are known to play a critical role in controlling fungal infections. However, the effect of HIV infection on innate and adaptive antifungal immunity remains unclear. Here, we review recent advances in understanding the fungal microbiota composition and common fungal diseases in the setting of HIV. Moreover, we discuss innate and adaptive antifungal immunity in HIV infection.

KEYWORDS
mycobiome, fungal diseases, fungal microbiota, antifungal immunity, HIV

Introduction

The human mycobiome inhabits the skin, respiratory tract, gastrointestinal tract, genitourinary tract, and other mucosal surfaces of the host. It has been shown that over 600 different fungi can cause disease in humans (1). In addition, over 300 million people are affected by serious fungal diseases, causing over 1.6 million deaths each year (2). The
increased incidence of global epidemic mycoses might be attributed to changes in the environment, population growth in endemic areas, and increased human immunodeficiency virus (HIV)-related immunosuppressive status (3).

In HIV infection, differences in bacterial population composition, including the oral microbiome (4, 5), lung microbiome (6, 7) and gut microbiome (8, 9), have been reported in HIV-infected compared to uninfected individuals. In addition, immunity compromised by HIV infection may lead to altered fungal composition, promoting the development of opportunistic fungal infections in HIV-infected individuals (10). It has been shown that opportunistic fungal infections have an unacceptably high toll on people living with HIV (PLWH) and are a major driver of HIV-related death (11). Although ART might decrease the mortality rate, the substantial burden of fungal disease remains high for HIV-infected individuals who are undiagnosed, untreated or fail ART (12). Fungal diseases in HIV infection have also not received sufficient attention from the global community (11).

It has been shown that host innate and adaptive immune responses play an important role in controlling fungal infections (13). Innate antifungal immune responses are triggered when fungal antigens, such as α- and β-glucans, O- and N-linked mannos, and chitin, stimulate pattern recognition receptors (PRRs) expressed on host cells, including C-lectin receptors (CLRs), NOD (nucleotide-binding and oligomerization domain)-like receptors (NLRs), and Toll-like receptors (TLRs), to initiate signal transduction cascades, which promote the production of chemokines and cytokines to eliminate fungal pathogens and activate adaptive responses (14). However, the substantial loss of CD4+ T cells in HIV infection might lead to deficiencies in antifungal immunity, contributing to an increased risk of opportunistic fungal infections. Furthermore, depletion of interleukin (IL)-17 and IL-22-producing T helper (Th) 17 cells might result in impaired integrity of mucosal epithelial barriers, leading to fungal translocation from the gut lumen into the systemic circulation (15, 16). Microbial translocation might contribute to HIV-associated immune activation and inflammation, as well as the development of non-AIDS events (15, 16).

Because appropriate culture conditions remain unclear, most of the human mycobiome is nonculturable by culture-dependent methods (17). However, with the advent of new techniques, next-generation sequencing has been widely used for mycobiome detection in recent years (18). Internal transcribed spacer (ITS) sequencing and 18S rRNA are the most applied techniques to detect the mycobiome (19). In this review, we discuss alterations in the mycobiome and common fungal diseases in HIV infection, as well as the effects of HIV infection on innate and adaptive antifungal immunity.

Alterations of the mycobiome in HIV infection

The oral mycobiome in HIV infection

Alterations in oral bacterial communities and virome in HIV-infected individuals have been reported in many studies (4, 5, 20–22). The possible reasons for oral microbiome dysbiosis might be the disrupted oral immunity caused by HIV infection, including changes in secretory components in saliva, deficiency of innate immune responses and adaptive immune responses (5).

In addition to oral bacterial and virus communities, the oral mycobiome might contribute to understanding host–pathogen interactions that occur in HIV infection (23). For example, Ghannoum et al. characterized the oral mycobiome in healthy individuals using ITS sequencing (24), detecting 74 culturable and 11 nonculturable fungal genera (24). Candida species were the most frequent of the oral mycobiome (isolated from 75% of participants), followed by Cladosporium (65%), Aureobasidium and Saccharomyces (50%, respectively) (24). Previous studies have demonstrated that oral fungal colonization is altered in HIV infection (25–28) (Table 1). In HIV-infected individuals, Candida (92%), Epicoccum (33%), and Alternaria (25%) are the most common genera in the oral mycobiome, whereas the most abundant oral mycobiome genera in HIV-uninfected controls are Candida, Pichia, and Fusarium, present in 58%, 33%, and 33%, respectively (25, 26). A recent study also compared the oral mycobiome between 30 HIV-infected individuals and 30 healthy controls and explored the effect of ART on the oral mycobiome in HIV infection. They found Candida, Mortierella, Malassezia, Simplicillium, and Penicillium to be significantly increased in HIV-infected individuals and dramatically decreased after ART. In contrast, the abundances of Verticillium, Issatchenka, and Alternaria were significantly increased in PLWH after ART (27). They found that the composition of the oral mycobiome in the HIV-infected subjects after 6 months of ART was similar to that in the HIV-uninfected individuals. Moreover, Mortierella, Malassezia, Simplicillium, and Chaetomium were positively associated with viral load (VL), and Verticillium, Thysrostrum and Archaeorhizomyces were negatively associated with VL and positively correlated with CD4+ T-cell counts. In addition, Saccharomyces was positively correlated with VL and negatively associated with CD4+ T-cell counts (27). Therefore, HIV infection and ART administration might impact on the composition of the oral mycobiome, and the dysbiosis of oral mycobiome in HIV infection could be partially restored after ART. Furthermore, some oral fungi were sensitive to the changes in CD4+ T-cell counts and VL in the blood of HIV-infected individuals, thus changes in the oral mycobiome in HIV infection after ART may reflect the immune status of patients.
The respiratory tract mycobiome in HIV infection

Due to incomplete restoration of pulmonary immunity with ART, HIV-infected individuals continue to have high burdens of pulmonary comorbidities, including chronic obstructive pulmonary disease (COPD) (34, 35), lung cancer (36–38), pulmonary fibrosis (39) and pulmonary emphysema (39–41). Overall, the complex respiratory tract microbiome, including the lung mycobiome, may play an important role in lung disease (42).

Previous studies have indicated that the diversity and composition of the lung microbiome in HIV-infected patients are altered compared with HIV-uninfected individuals (43–45) (Table 1). In addition, studies have also reported alterations in the respiratory tract mycobiome in HIV-infected individuals. Bittinger et al. analyzed bronchoalveolar lavage (BAL) samples from 42 lung transplant patients, 19 HIV-positive patients, 13 patients with various pulmonary diseases and 12 healthy controls; only low levels of fungal reads were detected in the healthy individuals, and the fungi detected comprised taxa with little clinical significance, except for Aspergillus. Conversely, clinical pathogens such as Pneumocystis, Cryptococcus, and Aspergillus were found in BAL of HIV-infected subjects (30). Another study published by Cui et al. compared fungal communities in the respiratory tract from 24 healthy subjects and 32 HIV-infected subjects; 9 species were overrepresented in the BAL of HIV-infected subjects, including Pneumocystis jirovecii, Junghuhnia nitida, Phlebia tremellosa, Oxyoporus late-marginalis, Sebacina in-crustans, Ceriporia lacerata, Pezizella discrete, Trametes hirsute, and Daedaleopsis confragosa (29). Of these species, Pneumocystis jirovecii pneumonia (PCP) is one of the most common opportunistic infections in PLWH. These data reveal that alterations in the respiratory tract mycobiome might be an important driver of opportunistic infection in HIV-infected individuals.

The gut mycobiome in HIV infection

The gut microbiome is being progressively recognized as playing an important role in promoting immune activation and inflammation in HIV infection. Dysbiosis of the gut microbiome

| References | Study cohort | Samples | Design | Mycobiome alterations |
|------------|--------------|---------|--------|----------------------|
| Chang et al. (27) | 30 HIV+ subjects prior to and after 6 months of ART and 30 healthy controls | Saliva | Cross-sectional and longitudinal | Increased Candida, Mortierella, Malassezia, Simplicillium, and Penicillium in the HIV group, decreasing after ART. Increased Verticillium, Isatrichnum, and Alternaria in HIV+ subjects after ART. |
| Fidel et al. (28) | 149 HIV+ subjects and 88 HIV- subjects | Oral rinse | Cross-sectional | Predominated by four major clusters: Candida albicans, Candida dublilienis, Malassezia restricta, and Saccharomyces cerevisiae. Several clinical variables affect the oral mycobiome, including HIV positivity and ART. |
| Mukherjee et al. (25) | 12 HIV-infected and 12 uninfected individuals | Oral rinse | Cross-sectional | Enrichment of Candida, Epicoccum, and Alternaria in HIV-infected individuals (present in 92%, 33%, and 25%, respectively) and Candida, Pichia, and Fusarium in uninfected individuals (58%, 33%, and 33%, respectively). |
| Cui et al. (29) | 32 HIV-infected and 24 HIV-uninfected individuals | Oral washes, induced sputa, and BAL | Cross-sectional | Increased Pneumocystis jirovecii, Junghuhnia nitida, Phlebia tremellosa, Oxyoporus late-marginalis, Sebacina in-crustans, Ceriporia lacerata, Pezizella discrete, Trametes hirsute, and Daedaleopsis confragosa in HIV-infected individuals. |
| Bittinger et al. (30) | 19 HIV+ subjects and 12 healthy controls | Oropharyngeal wash and BAL | Cross-sectional | Increased clinical pathogens Pneumocystis, Cryptococcus, and Aspergillus in HIV-infected individuals. |
| Hamad et al. (31) | 31 HIV-infected individuals and 12 uninfected HIV individuals | Fecal | Cross-sectional | Enriched Ascomycota, Pichia, Penicillium brevicipactum and Penicillium in healthy controls and enriched Candida albicans and Candida tropicalis in HIV-infected individuals. |
| Wu et al. (32) | 75 HIV-infected patients and 55 HIV-uninfected participants | Fecal | Cross-sectional | Nectriaeaceae, Hypocreales, and Sordariomycetes were the top 3 fungal taxa in HIV-infected individuals. While Basidioymycota, Phallaeae, and Phallales were particularly enriched in HIV-uninfected controls. |
| Yin et al. (33) | 18 HIV-infected patients and 22 healthy controls | Fecal | Cross-sectional | Aspergillus was the most abundant genus (49.92%) in the HIV-infected group, while the most abundant fungal genus was Candida (38.31%) in the healthy controls. Unclassified Asgillicaceae and Dirkmeia were enriched in the high-CD4+ T-cell group, while Candida, Sordariales, Saccharomycetaceae, and Neosaccharomyces were enriched in the low-CD4+ T-cell group. |

HIV, human immunodeficiency virus; ART, antiretroviral therapy; BAL, bronchoalveolar lavage.
has been demonstrated in many studies (9, 46, 47), and such alterations of the gut microbiome composition in HIV infection might be attributed to the loss of appropriate innate and adaptive immune responses (48).

In the human gut, the diversity of the fungal community is much lower than that of the bacterial microbiota (49). Fungi in the gastrointestinal tract are often ignored, as fungi comprise a tiny fraction of the gut microbes and most are unculturable. Previous studies have been shown that Candida, Saccharomyces, Aspergillus, Cryptococcus, Malassezia, Cladosporium, Galactomyces and Trichosporon can grow at 37°C and therefore have the potential to permanently colonize in the gut (50). In addition, although Histoplasma spp., Coccidioides spp. and Blastomyces spp. cannot colonize the mucosal surfaces, they can cause severe lung infections (51) (Figure 1). A recent study investigated the gut mycobiome of the Human Microbiome Project (HMP) cohort and revealed Saccharomyces, Malassezia, and Candida to be the most abundant genera present in this cohort (49). In a study of 96 healthy individuals, the most common genera in fecal samples were Saccharomyces, Candida and Cladosporium (present in 89%, 57% and 42%, respectively) (52). Another study showed that the most prevalent genus in healthy individuals is Penicillium (present in 73% of samples), followed by Candida and Saccharomyces (55% for both), Mucor (38%) and Aspergillus (35%) (53). Additionally, gut mycobiome alterations in HIV infection have been reported (Table 1). Gouba et al. found decreased fungal species diversity in HIV-infected individuals (54), showing significantly more abundance of Candida spp. in HIV-infected patients than in healthy individuals. Candida albicans in the gut can affect many processes, such as digestion and immunity (55). Candida spp. are more prevalent in HIV-infected individuals with diarrhea and

FIGURE 1
Impact of HIV infection on innate and adaptive immune responses to opportunistic fungal pathogens. HIV infection might lead to impairment of the innate and adaptive arms of the immune system, resulting in susceptibility to opportunistic fungal infections. Neutrophils control fungal infections through multiple mechanisms, including AMPs, ROS and NETs. Macrophages directly kill invading fungi through phagocytosis. DCs recognize fungal antigens by PRRs and also promote Th1 and Th17 immunity, as well as antibody production, to clear fungal infections. HIV can not only lead to impairment of neutrophil responses, phagocytosis of macrophages and the antigen presentation capacity of DCs but also cause defects in Th1, Th12 and B-cell responses. Abbreviations: AMPs, antimicrobial peptides; ROS, reactive oxygen species; NETs, neutrophil extracellular traps; DCs, dendritic cells; Th1, T helper 1 cell; Th17, T helper 1 cell; PRR, pattern recognition receptor.
recent antibiotic treatment than in healthy controls (54). Yin et al. showed that *Aspergillus* was the most abundant genus (49.92%) in the HIV-infected group, while the most abundant fungal genus was *Candida* (38.31%) in the healthy controls (33). Wu et al. found that 4 taxa from Ascomycota and 16 taxa from Basidiomycota were differentiated between HIV-infected individuals and HIV-uninfected controls in the fungal linear discriminant analysis (LDA) analysis. *Nectriaceae*, *Hypocreales*, and *Sordariomycetes* were the top 3 fungal taxa in HIV-infected individuals. While *Basidiomycota*, *Phallaceae*, and *Phallales* were particularly enriched in HIV-uninfected controls (32). Another study also compared the fungal populations of fecal samples from HIV-infected individuals and healthy controls; *Ascomycota*, *Pichia*, *Penicillium brevicompactum* and *Penicillium* were more abundant in healthy controls, whereas the abundances of *Candida albicans* and *Candida tropicalis* were enriched in HIV-infected individuals (31). In addition, Yin et al. demonstrated the relationship between CD4+ T-cell counts and the gut mycobiome in the HIV-infected participants (33). They found that patients with low CD4+ T-cell counts and patients with high CD4+ T-cell counts have different fungal community characteristics. *Eurotiomycetes* was significantly decreased and *Saccharomycetes* was significantly increased in the low CD4+ T-cell group compared to the high CD4+ T-cell group. At the genus level, *Candida* was significantly increased in the low CD4+ T-cell group, indicating a high risk of opportunistic infection. Moreover, unclassified *Aspergillaceae* and *Dirkmeia* were enriched in the high CD4+ T-cell group, while *Sordariales*, *Saccharomycetaceae*, and *Neocosmospora* were enriched in the low CD4+ T-cell group. It has been shown that members of the genus *Neocosmospora* can lead to lung infections in liver transplant patients (56) and contain highly prevalent and aggressive fungal pathogens (57), suggesting that the immune T-cell reduction might expose patients to a state of high-risk infection.

The incidence of OPC in HIV infection is influenced by a multitude of factors (67), including immune status (68), bacteriome–mycobiome interaction (69), anti-fungal therapy and ART (70). Several studies have shown that a lower CD4+ T-cell count, especially below 200 cells/µl, is strongly associated with increased occurrence of OPCs (71–74). A reduction in CD4+ T cells, especially IL-17-producing cells, in the oral mucosa may be associated with susceptibility to OPC (75). In addition, impairment of oral immunity by the reduction of salivary components such as salivary IgA, defensins, and some cytokines might lead to the onset of OPC (76). However, host defense mechanisms executed by keratinocytes, calprotectin, CD8+ T cells, and phagocytes partly compensate for these defects, which may play a key role in controlling *C. albicans* proliferation and preventing systemic dissemination in HIV infection (68).

**Pneumocystis jirovecii pneumonia**

PCP is one of the most common opportunistic fungal infections in immunocompromised individuals and HIV-infected individuals (77, 78). In the late 1980s, PCP occurred in approximately 75% of HIV-infected individuals (79), though the incidence of HIV-associated PCP has decreased dramatically with the implementation of ART and chemoprophylaxis (80). Nonetheless, PCP continues to be a serious problem in HIV-infected patients who are undiagnosed and untreated or in those with ART failure (81). It is speculated that there are more than 400,000 cases of PCP worldwide each year (82, 83).

As mentioned above, PCP tends to occur most frequently when the CD4+ T-cell count is below 200 cells/µl (84–86), and CD4+ T cells, CD8+ T cells, neutrophils, alveolar macrophages and soluble mediators have been implicated in clearance of PCP (87). Carmona et al. demonstrated that *Pneumocystis*-derived β-glucans activate dendritic cells (DCs) through the Fas ligand (FasL) mechanism and the Dectin-1 receptor, leading to increased expression of costimulatory molecules and T helper 1 (Th1) cell activation (88). Another study found that DCs stimulated by cell-surface β-glucan components of *Pneumocystis* interact with lymphocytes to produce IL-17 and IL-22 (89). Th1, Th2 and Th17 responses are essential in *Pneumocystis* clearance and contribute to host protection against this pathogen (90). However, Th2 and Th17 responses also play a role in *Pneumocystis*-driven pathology (90). In addition, the cytokines produced by CD4+ T cells, such as IFN-γ, also are important for the control of PCP (87, 90).

**Cryptococcal meningitis**

Cryptococcal meningitis (CM) is one of the most common opportunistic infections in the late stage of AIDS (91), and
Cryptococcus neoformans is the most common cause of death in HIV-infected individuals. An estimated 223,100 cases of CM occur globally each year, resulting in 181,100 deaths; 135,900 occur in sub-Saharan Africa, and CM accounts for 15% of all AIDS-related deaths (91). Despite effective ART and antifungal drugs, the mortality rate of CM in AIDS patients is still as high as 30%-50%, especially in patients in resource-poor areas (92–94).

Evidence suggests that host immune responses to cryptococcosis play a critical role in disease progression (95–97). CM can occur following primary lung infection or by reactivation and dissemination of latent pulmonary infection in the setting of cell-mediated immunodeficiency when CD4+ T-cell counts are <100 cells/µl in the late-stages of HIV-infection (98). Previous studies have shown that CD4+ T cells possibly mediate protective host immunity against cryptococcal via production of Th1-type cytokine responses, including IL-2, IL-12, tumor necrosis factor alpha (TNF-α), and IFN-γ, which play an essential role in recruitment of lymphocytes and phagocytes to clear the infection (99, 100). Higher levels of IFN-γ in cerebrospinal fluid (CSF) are associated with a faster rate of fungal clearance and lower fungal burdens (101, 102). Moreover, higher pre-ART levels of IL-4 and IL-17 and lower TNF-α, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF) and vascular endothelial growth factor (VEGF) might predict future immune reconstitution inflammatory syndrome (IRIS) (103).

Talaromyces marneffei infection

Talaromycosis is an invasive fungal disease caused by the opportunistic fungus Talaromyces marneffei (TM) and is prevalent mainly in Southeast Asia. Since the HIV pandemic, the prevalence of talaromycosis has rapidly increased, especially in areas of Southeast Asia, including Thailand, Vietnam and Myanmar, and East Asia, including South China, Hong Kong, Taiwan, and northeastern India (104). A recent study showed that the prevalence of TM infection in Asia was 3.6% in HIV-infected individuals (105). The prevalence of TM infection in HIV-infected individuals has been reported to be 6.4% in Vietnam, 3.9% in Thailand, 3.3% in China, 3.2% in India, and 2.1% in Malaysia (105). Furthermore, mortality rate of TM infection is reportedly higher than that of most HIV-related complications in PLWH (81). Although ART has led to a decline in the incidence of TM infection, it remains a major problem in undiagnosed and untreated HIV-infected individuals (81).

Innate and acquired immune responses play a crucial role in controlling TM infection (107). Innate immune cells, including monocytes (108), macrophages (109, 110), polymorphonuclear neutrophils (PMNs) (111), and DCs (112) have been shown to play an essential role in combating TM. These innate immune cells promote clearance of TM infection by producing proinflammatory cytokines such as IL-1β, TNF-α, and IFN-γ and anti-inflammatory cytokines such as IL-10 (107). A recent study also demonstrated that single-nucleotide polymorphisms (SNPs) in TLR2 might contribute to increased susceptibility and severity of TM in Han Chinese populations (113). Moreover, another study found that severe TM infection in Southeast Asia may be related to the high prevalence of anti-IFN-γ autoantibody-associated HLA-DRB1*16:02 and HLA-DQB1*05:02 alleles (114). A previous study found that HIV-infected individuals with CD4+ T-cell counts below 200 cells/µl had a higher risk of TM infection (105). In general, immune deficiencies that reduce CD4+ T cells and IFN-γ, IL-12, and IL-17 functions may be predisposing factors for TM infection, as evidenced by the high infection burden in advanced HIV-infected individuals, highlighting the important roles of Th1 and Th17 responses in host resistance to TM infection (115).

Histoplasmosis

Histoplasmosis is caused by Histoplasma capsulatum, which is a common endemic mycosis in PLWH (116). Globally, epidemic distribution of histoplasmosis mainly in regions of the Americas (81). In addition, histoplasmosis is also endemic in many Asia areas, including Southeast Asia, India, and China along the Yangtze River (117, 118). With the spread of HIV, the case-fatality rates of disseminated histoplasmosis increased among culture-positive cases, ranging from 10% to 53% (119). Disseminated histoplasmosis has been neglected due to its nonspecific symptoms, frequent misdiagnosis as tuberculosis, and insensitive diagnostic methods (120).

HIV-infected individuals are at greatly increased risk of developing histoplasmosis, especially those with CD4+ T-cell counts <200 cells/µl (121). Histoplasma capsulatum yeasts can infect macrophages and survive within phagocytic cells (122). The strategies of Histoplasma capsulatum against macrophages might include immune response evasion on entry, inactivation of nitrogen and oxygen reactive species, hindrance of lysosomal pH reduction, production of siderophore, prevention of phagolysosomal fusion, and induction of apoptosis (123). In addition to the control of Histoplasma capsulatum infection by cellular immune response, the roles of antibodies in the serodiagnosis of histoplasmosis have also been proposed. Almeida et al. characterized Histoplasma capsulatum proteins specifically recognized by antibodies in serum samples from histoplasmosis patients by an immunoproteomic approach (123).

Aspergillosis

Aspergillosis is a life-threatening fungal disease in immunocompromised individuals, including PLWH. Previous study has been shown that the incidence of aspergillosis was 3.5
cases per 1000 person-years among 35,252 HIV-infected individuals (124). Although aspergillosis occurs uncommonly in HIV-infected individuals, it is associated with a short lifespan after diagnosis.

It has been shown that older people, people with severe immunosuppression or advanced HIV disease, and people with leukopenia and neutropenia are at increased risk of developing aspergillosis (124). Before the advent of ART, invasive aspergillosis in HIV-infected individuals tended to occur when CD4 T-cell counts <100 cells/µl, especially in patients with prior or concomitant opportunistic infections (125). Therefore, modulation of host immunity plays a critical role in the control of aspergillosis. Animal studies in aspergillosis have also demonstrated beneficial effects of G-CSF, GM-CSF, IFN-γ, and monoclonal antibodies (126).

### Antifungal immunity in HIV infection

#### Innate antifungal immunity in HIV infection

The innate immune response is the first line of defense against fungal infections (127). Innate immune cells, such as neutrophils, monocytes, macrophages, and dendritic cells, are known to have a crucial function in recognizing and clearing fungi, inducing protective immune responses, and initiating adaptive immune responses during fungal infections (127, 128). Neutrophils control fungal infections through multiple mechanisms, including production of granule proteins, antimicrobial peptides (AMPs) and reactive oxygen species (ROS) and formation of neutrophil extracellular traps (129, 130). Indeed, neutrophils are critical cells against Candida spp. and Aspergillus spp (131). Macrophages not only directly kill invading fungi through phagocytosis but also initiate and regulate downstream immune responses to clear fungal infections by releasing cytokines, presenting antigens, and recruiting other immune cells (132). Fungal antigens are also recognized by DCs mediated by CLRs, including dectin-1, dectin-2 and DC-SIGN, as well as TLRs, including TLR2, TLR4 and TLR9 (133). DCs might also collaborate with other immune cells, such as Group 2 innate lymphoid cells (ILC2s), to promote innate antifungal immune responses and regulate adaptive immune responses (130). Nevertheless, the effect of HIV infection on innate antifungal immunity remains unclear.

HIV does not directly infect neutrophils but can cause impaired neutrophil responses, leading to impaired bacterial and fungal killing, which might result in increased susceptibility to bacterial infections and mycoses (134). Enomoto et al. found that anti-cryptococcal activity in HIV-infected patients is enhanced by administration of granulocyte colony stimulating factor (G-CSF) to enhance neutrophil defense (135). Moreover, Kalem et al. showed that HIV-1 infection of THP-1 macrophages increases the rate of Cryptococcus neoformans cell phagocytosis (136); these authors revealed that macrophages infected with HIV-1 alone might upregulate production of TNF-α and activate NF-kB signaling but that Cryptococcus neoformans coinfection rapidly represses this proinflammatory response (136). In addition, HIV-infected macrophages might contribute to increased susceptibility to opportunistic fungal infections (137). Studies have indicated that HIV infection of macrophages impairs the phagocytosis and killing of Pneumocystis jirovecii (138), Candida albicans (139) and Aspergillus fumigatus (140). A possible reason is that the HIV-1 accessory proteins Nef and Tat downregulate the mannose receptor expressed on the surface of macrophages. It has also been shown that HIV-1 reduces the number of DCs and disrupt their function. In HIV infection, DCs have a reduced ability to present antigens and stimulate T-cell proliferation and show a partially activated phenotype and impaired TLR responses (141, 142). T-cell proliferation in HIV-infected individuals might be inhibited by plasmacytoid DCs (pDCs) via induction of indoleamine-2,3-dioxygenase (IDO) (143). IDO expression by pDCs also blocks T-cell differentiation into Th17 cells, which might have a negative effect in adaptive antifungal immunity and predispose patients toward opportunistic infections, such as fungal infections with C. albicans and C. neoformans (141). Overall, HIV infection might lead to quantitative and qualitative deficiencies in innate antifungal immunity (Figure 1).

#### Adaptive antifungal immunity in HIV infection

CD4+ T cells are generally considered to play an important role in defense against fungal infections. The importance of Th1 and Th17 responses in antifungal defense mechanisms has been described (144). It is well known that the Th1 response provides protective immunity mainly through production of proinflammatory cytokines, such as IFN-γ, IL-2, IL-12, and TNF-α (144). The IFN-γ produced by Th1 cells activates macrophages, such as macrophages, and promotes phagocytosis, MHC-II molecule upregulation and antigen presentation by APCs (145). Enhanced protection against Aspergillosis, Cryptococcus, and coccidioidomycosis has been demonstrated in patients receiving IFN-γ immunotherapy (146). Th17 cells produce cytokines, including IL-17A, IL-17F, and IL-22, which promote neutrophil recruitment and fungicidal activity and induce production of AMPs from epithelial cells and keratinocytes to prevent fungal overgrowth (145). The Th17 response has been shown to play an essential role in promoting clearance of fungi, such as Candida albicans and Malassezia spp (147). In addition, antibodies are important in limiting the fungal burden and its clearance (148). Antibodies can defend against fungal pathogens through direct mechanisms, including...
infection might lead to impaired antifungal immunity (Figure 1). Antibody responses to Cryptococcus neoformans (149) and Candida albicans (150) have been reported.

HIV infection leads to a rapid and massive reduction in CD4+ T cells. One recent study showed that levels of Th1 cytokines in CSF, including IL-12 and TNF-α, correlate positively with HIV-associated cryptococcal meningitis (151). Moreover, in HIV-infected individuals, IFN-γ produced by Th1 cells plays an important function in improving the antifungal immune response to cryptococcal infection (102) and oral candidiasis (152). Jarvis et al. found that the Th1 responses of Cryptococcus-specific CD4+ T cells play a key role in promoting circulating lymphocyte and monocyte recruitment to the central nervous system (CNS), CNS macrophage and microglial activation and organism clearance (153). In addition to the Th1 response, Th17 cells are critical in defense against bacterial and fungal infections at mucosal sites (154, 155). However, Liu et al. found that Th17-associated functions (IL-22, IL-17 and IL-2) of Candida albicans-specific CD4 T cells are disrupted in early HIV infection (156). Early massive loss of Th17 cells in HIV infection has also been shown to be a likely cause of the high prevalence of chronic mucocutaneous candidiasis in people with early HIV infection (157). Therefore, mucosal candidiasis susceptibility in HIV infection may be attributed to Th17-cell depletion.

HIV-1 replication might lead to abnormalities in all major lymphocyte populations as well as hyperactivation and exhaustion of the B-cell compartment (158). Studies have found that impaired B-cell responses due to HIV infection might affect B-cell responses in cryptococcal coinfection (159, 160). Moreover, levels of antibodies, such as plasma IgM, laminarin (Lam)-binding IgM and IgG, are significantly lower in HIV-infected individuals who develop Cryptococcus-associated IRIS than in those who do not, supporting the role of advanced HIV infection. Despite widespread use of ART, fungal opportunistic infections are the leading cause of HIV-related death globally. It is evident that human immune responses play a critical role in defense against fungal infection. We review the impact of HIV infection on host innate and adaptive antifungal immunity, contributing to a better understanding of the underlying immunopathogenesis of fungal infections in HIV infection. In addition, further efforts to develop new diagnostics and global access to antifungal drugs and other effective therapies are needed to enable early diagnosis and treatment of fungal infections.

Author contributions

BS and TZ conceptualized and supervised the whole study, SL, XY, HW, BS, and TZ searched the literature, contributed to the analysis and provided important scientific input. SL, CM and BS wrote the first draft and revised version of the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This project is financially supported by the National Natural Science Foundation of China (NSFC, 82072271 and 81974303), Beijing Natural Science Foundation (Z220018), the High-Level Public Health Specialized Talents Project of Beijing Municipal Health Commission (2022-1-007 and 2022-2-018), the “Climbing the peak (Dengfeng)” Talent Training Program of Beijing Hospitals Authority (DFL20191701), the Beijing Health Technologies Promotion Program (BHTPP2020), and Beijing Key Laboratory for HIV/AIDS Research (BZ0089). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Infect Dis associated cryptococcal meningitis: a randomized controlled trial. Adjunctive interferon-gamma immunotherapy for the treatment of HIV-associated cryptococcal meningitis: implications for improving outcomes. Determinants of mortality in a combined cohort of 501 patients with HIV- doi: 10.1186/s12879-021-06138-z BMC Infect Dis cells orchestrate lethal immune pathology despite fungal clearance during cryptococcus neoformans meningoencephalitis. mBio weak or strong immune response. Frontiers inImmunology frontiersin.org11 update by the infectious diseases society of america. et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 global call for talaromycosis to be recognised as a neglected tropical disease. mibio

102. Jarvis JN, Meintjes G, Rebe K, Williams GN, Bicanic T, Williams A, et al. Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome. Clin Infect Dis (2020) 9(11):e1618. doi:10.1093/cid/ciac514. doi: 10.3389/fcimb.2020.591121

104. Narayanasamy S, Dat VQ, Thanh NT, Ly VT, Chan JF, Yuen KY, et al. A preliminary study on the engagement of penicillium marneffei conidia with multiple pattern recognition defense mechanisms. Front Cell Infect Microbiol

105. Qin Y, Huang X, Chen H, Liu X, Li Y, Hou J, et al. Burden of talaromyces marneffei infection on mortality of HIV/AIDS patients in southern China: a systematic review and meta-analysis. Infect Drug Resist (2021) 14(1):30243-8.

106. Loyse A, Thangaraj H, Easterbrook P, Ford N, Roy M, Chiller T, et al. Cryptococcal meningitis: impact of access to essential antifungal medicines in resource-poor countries. Lancet Infect Dis (2013) 13(7):629–37. doi: 10.1016/S1473-3099(13)70078-1

107. Loyse A, Burry J, Cohn J, Ford N, Chiller T, Ribeiro I, et al. Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries. Lancet Infect Dis (2019) 19(4):e143–7. doi: 10.1016/S1473-3099(18)30493-9

108. Perez-Jacostis Asma MA, Bishai O, Ibarraen JA, Perez-Rivella A, Micran R, Dronda F, et al. Cryptococcal infection in HIV-infected patients with CD4+ T-cell counts under 100/ml, diagnosed in a high-income country: a multicentre cohort study. Clin Microbiol Infect (2021) 27(8):e1171–1171. doi:10.1016/j.cmi.2020.09.053

109. Iyer KR, Revie NM, Fu C, Robbins N, Cowen LE. Treatment strategies for cryptococcal meningitis: advances and future outlook. Nat Rev Neurol (2017) 13(19):454–66. doi:10.1038/nrneurol.2017.111

110. Li A, Zhu W, Yin J, Huang X, Sun L, Hua W, et al. A preliminary study on the characteristics of Th1/Th2 immune response in cerebrospinal fluid of AIDS patients with cryptococcal meningitis. BMC Infect Dis (2021) 21(1):500. doi:10.1186/s12879-021-02247-x

111. Ellett F, Pazhakh V, Pase L, Benard EL, Weerasinghe H, Arabaddafar D, et al. Macrophages protect talarmyces marneffei conidia from myeloperoxidase-dependent neutrophil fungicidal activity during infection establishment in vivo. PLoS Pathog (2018) 14(6):e1007063. doi:10.1371/journal.ppat.1007063

112. Yang, Zhang H, Xu H, Zeng W, Qiu Y, Tan C, et al. Dendritic cells promote treg expansion but not Th17 expansion in response to talarmycosis murine yeast cells. Infect Drug Resist (2020) 13:805–13. doi: 10.2147/IDR.S239996

113. Wang M, Li L, Xiao S, Chen W, Hu F, Li F, et al. The association of TLR2, TLR3, and TLR9 gene polymorphisms with susceptibility to talarmycosis among han Chinese AIDS patients in guangdong. Front Cell Infect Microbiol (2021) 11:625461.

114. Gao J, Ning XQ, Ding FY, Zheng YQ, Shi NN, Wu FY, et al. Anti-IFN-gamma autoantibodies underlie disseminated talarmyces marneffei infections. J Exp Med (2020) 217(12):e20190502. doi:10.1029/20190502

115. Manion M, Boulougoura A, Naqvi N, Lage SL, Richards E, Grivas C, et al. Polynuclear antigen specific CD4+ T-cell responses in patients with HIV/AIDS and histoplasmosis immune reconstitution inflammatory syndrome. Clin Infect Dis (2022) 64(2):514. doi:10.1093/cid/ciac514

116. Manion M, Boulougoura A, Naqvi N, Lage SL, Richards E, Grivas C, et al. Polynuclear antigen specific CD4+ T-cell responses in patients with HIV/AIDS and histoplasmosis immune reconstitution inflammatory syndrome. Clin Infect Dis (2022) 64(2):514. doi:10.1093/cid/ciac514

117. Chen H, Yuan Q, Hu H, Wang J, Yu M, Yang J, et al. Hemophagocytic lymphohistiocytosis secondary to disseminated histoplasmosis in HIV seronegative patients: A case report and review of the literature. Front Cell Infect Microbiol (2020) 12:847950. doi:10.3389/fcimb.2020.847950

118. Wheat LJ, Azar MM, Bahr NC, Spec A, Relich RF, Hage C. Histoplasmosis. Infect Dis Clin North Am (2016) 30(1):207–27. doi:10.1016/j.idcl.2015.10.009

119. Adenis AA, Valdes A, Croquet C, McCotter OZ, Derado G, Coupie P, et al. Burden of HIV-associated histoplasmosis compared with tuberculosis in Latin America: a modelling study. Lancet Infect Dis (2018) 18(10):1150–9. doi:10.1016/S1473-3099(18)30534-2

120. Basso RP, Poester VR, Benelli JL, Stevens DA, Xavier MO. Disseminated histoplasmosis in persons with HIV/AIDS, southern Brazil, 2010–2019. Emerg Infect Dis (2022) 28(3):721–4. doi:10.3201/2003.211250

121. Tobon AM, Gomez BL. Pulmonary histoplasmosis. Mycopathologia (2021) 186(5):697–705. doi:10.1007/s11046-021-00588-4

122. Garfoot AL, Rappelye CA. Histoplasma capsulatum surmounts obstacles to intracellular pathogenesis. FEBS J (2016) 283(4):619–33. doi:10.1111/febs.13389

123. Almeida MA, Almeida-Paes R, Guimaraes AJ, Valente RH, Soares CMA, Zancole-Offeira VM. Antimicrobialproteins reveals pathogen’s antigens involved in homo sapiens-histoplasma capsulatum interaction and specific linear b-cell epitopes in histoplasmosis. Front Cell Infect Microbiol (2020) 10:591121. doi:10.3389/fcimb.2020.591121

124. Holding KJ, Dworkin MS, Wan PC, Hanson DL, Klevens RM, Jones JL, et al. Aspergillosis among people infected with human immunodeficiency virus: incidence and survival. Adult AdMesc Spectr HIV Dis Project Clin Infect Dis (2000) 31(5):1253–7. doi:10.1086/371422

125. Denis B, Guiguet M, de Castro N, Mecha F, Revet M, Mélaca G, et al. Relevance of EORTC criteria for the diagnosis of invasive aspergillosis in HIV-infected patients, and survival trends over a 20-year period in France. Clin Infect Dis (2021) 61(8):1273–80. doi:10.1093/cid/ciaa92

126. Sorensen JE, Tenforde MW, Levit SM, Jarvis IN. Modulating host immune responses to fight invasive fungal infections. Curr Microbiol (2017) 64:905–103. doi:10.1007/s00284-017-1008-0

127. Ward RA, Vyas JM. The first line of defense: effector pathways of anti-fungal innate immunity. Curr Microbiol (2020) 80:169–5. doi:10.1007/j.2018.01003

128. Kumar V, van de Veerdonk FL, Netea MG. Antifungal immune responses: emerging host-pathogen interactions and translational implications. Genome Med (2018) 10(1):39. doi:10.1186/s13073-018-0553-2

129. Underhill DM, Pearlman E. Immune interactions with pathogenic and commensal fungi: A two-way Street. Immunity (2015) 43(5):845–58. doi:10.1016/j.immuni.2015.10.023

130. Bartemes RK, Kita H. Innate and adaptive immune responses to fungi in the airway: J Allergy Clin Immunol (2018) 142(2):353–66. doi:10.1016/j.jaci.2018.06.015

131. Desai JV, Laniakis MS. The role of neutrophils in host defense against invasive fungal infections. Curr Microbiol Rep (2018) 5(3):181–9. doi:10.1007/s40588-018-0099-6
